Cargando…

Preventive strategies of cancer therapeutics-related cardiotoxicity in childhood cancer survivors: a protocol of systematic review

INTRODUCTION: Five-year survival in childhood cancer has been improved markedly in the past decades. Childhood cancer survivors are at high risk of cardiovascular diseases due to anticancer therapy-induced cardiotoxicity. The comprehensive evidence for the prevention of anticancer therapy-induced ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xin-Yu, Wang, Quan, Yang, Ke-Lu, Wei, Dang, Liu, Xiao-Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490564/ https://www.ncbi.nlm.nih.gov/pubmed/36127118 http://dx.doi.org/10.1136/bmjopen-2022-065776

Ejemplares similares

Can Dietary Nutrients Prevent Cancer Chemotherapy-Induced Cardiotoxicity? An Evidence Mapping of Human Studies and Animal Models
por: Zhang, Xin-Yu, et al.
Publicado: (2022)

Cardiotoxicity of Anticancer Therapeutics
por: Dong, Jerry, et al.
Publicado: (2018)

Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)
por: Maier, Rebecca H, et al.
Publicado: (2022)

Cardiac Function After Cardiotoxic Treatments for Childhood Cancer—Left Ventricular Longitudinal Strain in Screening
por: Niemelä, Jussi, et al.
Publicado: (2021)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
por: Vuong, Jacqueline T., et al.
Publicado: (2022)

Role and molecular mechanism of traditional Chinese medicine in preventing cardiotoxicity associated with chemoradiotherapy
por: Lv, Xin-Fang, et al.
Publicado: (2022)

Health-Related Physical Fitness and Arterial Stiffness in Childhood Cancer Survivors
por: von Korn, Pia, et al.
Publicado: (2019)

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
por: Morelli, Marco Bruno, et al.
Publicado: (2022)

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
por: Bansal, Neha, et al.
Publicado: (2019)

D-Dimer Is a Predictive Factor of Cancer Therapeutics-Related Cardiac Dysfunction in Patients Treated With Cardiotoxic Chemotherapy
por: Oikawa, Masayoshi, et al.
Publicado: (2022)

High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
por: Kluck, George E. G., et al.
Publicado: (2020)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Non-coding RNAs in cancer therapy-induced cardiotoxicity: Mechanisms, biomarkers, and treatments
por: Sun, Wanli, et al.
Publicado: (2022)

Emerging roles of circular RNAs in cancer therapy-induced cardiotoxicity
por: Cheng, Ziji, et al.
Publicado: (2023)

Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications
por: Kwok, Cecilia, et al.
Publicado: (2023)

Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies
por: Sangweni, Nonhlakanipho F., et al.
Publicado: (2022)

Local arterial stiffness measured by ultrafast ultrasound imaging in childhood cancer survivors treated with anthracyclines
por: Rasouli, Rahna, et al.
Publicado: (2023)

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy
por: Huang, Wei, et al.
Publicado: (2022)

Editorial: Novel mechanisms, imaging approaches, and management strategies for anthracycline-induced cardiotoxicity
por: Packard, René R. Sevag, et al.
Publicado: (2023)

Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery
por: Liu, Yihua, et al.
Publicado: (2023)

Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors
por: Sadurska, Elżbieta
Publicado: (2015)

Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis
por: He, Dongsheng, et al.
Publicado: (2022)

Genetics of Anthracycline-Associated Cardiotoxicity
por: Al-Otaibi, Talal Khalid, et al.
Publicado: (2022)

Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity
por: Kang, Dong-Woo, et al.
Publicado: (2022)

Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
por: Li, Mo-Yun, et al.
Publicado: (2022)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

The broad spectrum of cardiotoxicities from immunotherapies
por: Iengo, Martina, et al.
Publicado: (2023)

Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis
por: Jin, Hao, et al.
Publicado: (2023)

Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer
por: Posch, Florian, et al.
Publicado: (2022)

Systolic myocardial function measured by echocardiographic speckle-tracking and peak oxygen consumption in pediatric childhood cancer survivors—a PACCS study
por: Engan, Britt, et al.
Publicado: (2023)

Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments
por: Zhang, Guoxia, et al.
Publicado: (2022)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)

Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
por: Robinson, Emma L., et al.
Publicado: (2023)

Risk of cardiovascular disease among cancer survivors: Protocol of a pooled analysis of population-based cohort studies
por: Yu, Botao, et al.
Publicado: (2022)

Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal
por: Camilli, Massimiliano, et al.
Publicado: (2023)

Review on the Role of Epigenetic Modifications in Doxorubicin-Induced Cardiotoxicity
por: Kumari, Himani, et al.
Publicado: (2020)

Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments
por: Audebrand, Anais, et al.
Publicado: (2020)

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
por: Murabito, Alessandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_njs35q325mdan8l2c0v2ht3gpq